Agilent and SomaLogic said this week that they have entered an agreement to expand access to SomaLogic's SOMAscan protein biomarker discovery platform by placing it in select academic and contract research centers.

According to SomaLogic CEO Larry Gold, the move comes in response to growing demand for the platform, which the company has been offering out of its laboratory on a fee-for-service basis. SomaLogic has run more than 40,000 samples on the platform since launching it two years ago, Gold told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.